Actinium: Positive Full Data Results From Pivotal Phase 3 Trial in Acute Myeloid Leukemia

  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm

-  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients

-  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001

-  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover

-  Iomab-B was well tolerated with a favorable safety profile – 4 times lower rate of sepsis than control arm

-  Company to host conference call and webcast on Saturday, February 18, 2023 at 6:00 PM EST to highlight full SIERRA results

Investor Conference Call and Webcast Details:

Time / Date:	6:00 PM EST on Saturday, February 18, 2023
Presenters:	Sandesh Seth, Chairman & CEO
	Madhuri Vusirikala M.D., VP, Clinical Development – BMT & Cellular Therapy
	Avinash Desai, M.D., Chief Medical Officer
	Caroline Yarbrough, Chief Commercial Officer
Dial-in:	1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link and requesting a return call
Live webcast:	To access the live webcast of the call with slides please visit the Investors section of Actinium's website https://ir.actiniumpharma.com/presentations-webinars or https://viavid.webcasts.com/starthere.jsp?ei=1590226&tp_key=580722640c

An archived webcast will be available on the Actinium's website (click here) after the event.

https://finance.yahoo.com/news/actinium-announces-positive-full-data-213000850.html